Patent ID: 9556277
Date: 2017-01-31
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method for treating a disease or disorder which is ameliorated, improved or inhibited by blocking or inhibiting TL1A activity, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated human antibody or antigen-binding fragment thereof that specifically binds human TNF-like ligand 1A (hTL1A), comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2 and HCDR3 and a light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 sequence combination of HCDR 1/HCDR2/HCDR3/LCDR 1/LCDR2/LCDR3, selected from SEQ ID NO:4/6/8/12/14/16, 20/22/24/28/30/32, and 52/54/56/60/62/64, and a pharmaceutically acceptable carrier.